JP2020528765A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528765A5 JP2020528765A5 JP2020526685A JP2020526685A JP2020528765A5 JP 2020528765 A5 JP2020528765 A5 JP 2020528765A5 JP 2020526685 A JP2020526685 A JP 2020526685A JP 2020526685 A JP2020526685 A JP 2020526685A JP 2020528765 A5 JP2020528765 A5 JP 2020528765A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- antibody molecule
- antibody
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003308 immunostimulating effect Effects 0.000 claims 36
- 238000000034 method Methods 0.000 claims 31
- 206010028980 Neoplasm Diseases 0.000 claims 24
- 201000011510 cancer Diseases 0.000 claims 10
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 8
- 206010033128 Ovarian cancer Diseases 0.000 claims 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 6
- 201000009030 Carcinoma Diseases 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 206010029260 Neuroblastoma Diseases 0.000 claims 5
- 206010039491 Sarcoma Diseases 0.000 claims 5
- 208000008732 thymoma Diseases 0.000 claims 5
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 4
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 4
- 108010073807 IgG Receptors Proteins 0.000 claims 4
- 102000009490 IgG Receptors Human genes 0.000 claims 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 4
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims 4
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 4
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 4
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 4
- -1 ICOS Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 2
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 230000000779 depleting effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023106715A JP2023129433A (ja) | 2017-07-26 | 2023-06-29 | 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 |
| JP2025116576A JP2025157343A (ja) | 2017-07-26 | 2025-07-10 | 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1712032.0A GB201712032D0 (en) | 2017-07-26 | 2017-07-26 | Antibodies and uses thereof |
| GB1712032.0 | 2017-07-26 | ||
| PCT/EP2018/070359 WO2019020774A2 (en) | 2017-07-26 | 2018-07-26 | NOVEL ANTIBODIES AND COMBINED USE OF ANTIBODY THAT INDUCES TREG DEPLOYMENT AND AN IMMUNOSTIMULATOR ANTIBODY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023106715A Division JP2023129433A (ja) | 2017-07-26 | 2023-06-29 | 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020528765A JP2020528765A (ja) | 2020-10-01 |
| JP2020528765A5 true JP2020528765A5 (https=) | 2021-07-26 |
| JP7458973B2 JP7458973B2 (ja) | 2024-04-01 |
Family
ID=59771732
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526685A Active JP7458973B2 (ja) | 2017-07-26 | 2018-07-26 | 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 |
| JP2023106715A Pending JP2023129433A (ja) | 2017-07-26 | 2023-06-29 | 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 |
| JP2025116576A Pending JP2025157343A (ja) | 2017-07-26 | 2025-07-10 | 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023106715A Pending JP2023129433A (ja) | 2017-07-26 | 2023-06-29 | 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 |
| JP2025116576A Pending JP2025157343A (ja) | 2017-07-26 | 2025-07-10 | 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11447549B2 (https=) |
| EP (1) | EP3658587A2 (https=) |
| JP (3) | JP7458973B2 (https=) |
| CN (1) | CN111108124B (https=) |
| AU (1) | AU2018305209B2 (https=) |
| CA (1) | CA3070290A1 (https=) |
| GB (1) | GB201712032D0 (https=) |
| WO (1) | WO2019020774A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190017735A (ko) * | 2016-04-07 | 2019-02-20 | 캔써 리서치 테크놀로지 리미티드 | 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체 |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| CN112739339B (zh) | 2018-07-23 | 2024-12-27 | 海德堡医药研究有限责任公司 | 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
| ES2903440T3 (es) * | 2018-09-13 | 2022-04-01 | Euroimmun Medizinische Labordiagnostika Ag | Procedimiento y dispositivo para registrar y visualizar una imagen de inmunofluorescencia de una muestra biológica |
| NZ781538A (en) | 2019-04-24 | 2025-12-19 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| US20210038684A1 (en) * | 2019-06-11 | 2021-02-11 | Alkermes Pharma Ireland Limited | Compositions and Methods for Cancer Immunotherapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015237864B2 (en) * | 2014-03-24 | 2020-12-03 | Cancer Research Technology Limited | Modified antibodies containing modified IgG2 domains which elicit agonist or antagonistic properties and use thereof |
| WO2015188047A1 (en) * | 2014-06-06 | 2015-12-10 | University Of Maryland, Baltimore | ANTI-CD-137 MONOCLONAL ANTIBODIES WITH DISTINCT FcγR BINDING ABILITIES FOR TREATMENT OF CANCER OR AUTOIMMUNITY |
| EP3183269A2 (en) * | 2014-08-22 | 2017-06-28 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| JP6180663B2 (ja) | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| RS60614B1 (sr) | 2015-03-23 | 2020-08-31 | Jounce Therapeutics Inc | Antitela za icos |
| MX2017015937A (es) * | 2015-06-08 | 2018-12-11 | Genentech Inc | Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1. |
| GB201519481D0 (en) * | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| KR20190017735A (ko) | 2016-04-07 | 2019-02-20 | 캔써 리서치 테크놀로지 리미티드 | 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체 |
| BR112019025913A2 (pt) | 2017-06-09 | 2020-06-30 | Glaxosmithkline Intellectual Property Development Limited | métodos para tratar câncer em um paciente em necesssidade do mesmo e para produzir um anticorpo, anticorpo anti-icos ou fragmento de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou fragmento de ligação ao antígeno do mesmo, uso de um anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo na fabricação de um medicamento, polinucleotídeo que codifica um anticorpo, vetor, e, célula hospedeira. |
-
2017
- 2017-07-26 GB GBGB1712032.0A patent/GB201712032D0/en not_active Ceased
-
2018
- 2018-07-26 EP EP18753084.5A patent/EP3658587A2/en active Pending
- 2018-07-26 CA CA3070290A patent/CA3070290A1/en active Pending
- 2018-07-26 WO PCT/EP2018/070359 patent/WO2019020774A2/en not_active Ceased
- 2018-07-26 US US16/633,740 patent/US11447549B2/en active Active
- 2018-07-26 AU AU2018305209A patent/AU2018305209B2/en active Active
- 2018-07-26 CN CN201880050094.XA patent/CN111108124B/zh active Active
- 2018-07-26 JP JP2020526685A patent/JP7458973B2/ja active Active
-
2022
- 2022-08-11 US US17/819,234 patent/US20230058227A1/en active Pending
-
2023
- 2023-06-29 JP JP2023106715A patent/JP2023129433A/ja active Pending
-
2025
- 2025-07-10 JP JP2025116576A patent/JP2025157343A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528765A5 (https=) | ||
| JP2019500892A5 (https=) | ||
| JP2020508655A5 (https=) | ||
| JP2019500891A5 (https=) | ||
| JP2020520665A5 (https=) | ||
| HRP20171315T1 (hr) | Optimizacija humanih antitijela koja vezuju limfocitni aktivacijski gen-3 (lag-3), i njihove primjene | |
| JP2019513725A5 (https=) | ||
| JP2018532383A5 (https=) | ||
| HRP20251181T1 (hr) | Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene | |
| WO2019005641A1 (en) | GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF | |
| JP2019536470A5 (https=) | ||
| JP2021524248A5 (https=) | ||
| JP2019502676A5 (https=) | ||
| RU2018135247A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК | |
| JP2017531427A5 (https=) | ||
| JP2015535691A5 (https=) | ||
| CN107428832A (zh) | 抗pd‑l1抗体 | |
| HRP20240415T1 (hr) | Kimerni antigenski receptori antigena kapa mijeloma i njihova upotreba | |
| AU2020363041B2 (en) | Antibodies against the poliovirus receptor (PVR) and uses thereof | |
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| JP2019512207A5 (https=) | ||
| CN117946277A (zh) | 多特异性抗体及其制备和使用方法 | |
| CA3068045A1 (en) | Multi-specific antibodies and methods of making and using thereof | |
| JP2020502147A5 (https=) | ||
| RU2018143977A (ru) | Антитела анти-tnfrsf25 |